Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Myovant Sciences's selling, general, & admin. expense for the
three
months ended in Mar. 2022 was $67.2 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2022 was $259.4 Mil.
Myovant Sciences Selling, General, & Admin. Expense Historical Data
The historical data trend for Myovant Sciences's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Myovant Sciences Annual Data
Trend
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
Selling, General, & Admin. Expense
24.23
42.22
82.33
181.42
259.36
Myovant Sciences Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Selling, General, & Admin. Expense
78.04
61.21
58.78
72.13
67.25
Competitive Comparison
For the Biotechnology subindustry, Myovant Sciences's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myovant Sciences Selling, General, & Admin. Expense Distribution
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Selling, General, & Admin. Expense falls into.
Myovant Sciences Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $259.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myovant Sciences (NYSE:MYOV) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Myovant Sciences Selling, General, & Admin. Expense Related Terms
Thank you for viewing the detailed overview of Myovant Sciences's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.41(4.07%) Volume: 479,709 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MYOV has been successfully added to your 
